527 related articles for article (PubMed ID: 8542152)
1. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
[TBL] [Abstract][Full Text] [Related]
2. Mediastinal staging of non-small-cell lung cancer with positron emission tomography.
Chin R; Ward R; Keyes JW; Choplin RH; Reed JC; Wallenhaupt S; Hudspeth AS; Haponik EF
Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):2090-6. PubMed ID: 8520780
[TBL] [Abstract][Full Text] [Related]
3. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
[TBL] [Abstract][Full Text] [Related]
5. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.
Wahl RL; Quint LE; Greenough RL; Meyer CR; White RI; Orringer MB
Radiology; 1994 May; 191(2):371-7. PubMed ID: 8153308
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
7. [Positron emission tomography in the evaluation of intrathoracic lymphatic extension of non-small cell bronchial cancer. A preliminary study of 30 patients].
Bury T; Corhay JL; Paulus P; Weber T; D'Harcour JB; Limet R; Rigo P; Radermecker MF
Rev Mal Respir; 1996 Jul; 13(3):281-6. PubMed ID: 8765921
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer.
Roh JL; Ryu CH; Kim JS; Lee JS; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Sep; 43(8):757-63. PubMed ID: 17112773
[TBL] [Abstract][Full Text] [Related]
9. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling.
Steinert HC; Hauser M; Allemann F; Engel H; Berthold T; von Schulthess GK; Weder W
Radiology; 1997 Feb; 202(2):441-6. PubMed ID: 9015071
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of 11C-choline PET and [18F]fluorodeoxyglucose PET in the evaluation of lung cancer.
Khan N; Oriuchi N; Zhang H; Higuchi T; Tian M; Inoue T; Sato N; Endo K
Nucl Med Commun; 2003 Apr; 24(4):359-66. PubMed ID: 12673163
[TBL] [Abstract][Full Text] [Related]
11. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography.
Sasaki M; Ichiya Y; Kuwabara Y; Akashi Y; Yoshida T; Fukumura T; Murayama S; Ishida T; Sugio K; Masuda K
Eur J Nucl Med; 1996 Jul; 23(7):741-7. PubMed ID: 8662111
[TBL] [Abstract][Full Text] [Related]
12. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
Rege SD; Hoh CK; Glaspy JA; Aberle DR; Dahlbom M; Razavi MK; Phelps ME; Hawkins RA
Cancer; 1993 Jul; 72(1):82-90. PubMed ID: 8389668
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis of early cancer with positron emission tomography].
Kubota K
Nihon Rinsho; 1996 May; 54(5):1263-7. PubMed ID: 8965348
[TBL] [Abstract][Full Text] [Related]
14. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer.
Bury T; Paulus P; Dowlati A; Corhay JL; Weber T; Ghaye B; Schoffers J; Limet R; Albert A; Rigo P; Radermecker M
Eur Respir J; 1996 Dec; 9(12):2560-4. PubMed ID: 8980969
[TBL] [Abstract][Full Text] [Related]
15. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
16. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
17. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.
Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268
[TBL] [Abstract][Full Text] [Related]
18. Detection of scalene lymph node metastases from lung cancer. Positron emission tomography.
Scott WJ; Gobar LS; Hauser LG; Sunderland JJ; Dewan NA; Sugimoto JT
Chest; 1995 Apr; 107(4):1174-6. PubMed ID: 7705136
[TBL] [Abstract][Full Text] [Related]
19. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).
Schmid RA; Hautmann H; Poellinger B; Kellner W; Moisseev A; Brinkbaeumer K; Weiss M; Hahn K; Dresel S
Nucl Med Commun; 2003 Jan; 24(1):37-45. PubMed ID: 12501018
[TBL] [Abstract][Full Text] [Related]
20. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
Farrell MA; McAdams HP; Herndon JE; Patz EF
Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
